The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of HER2-positive breast cancer - received neoadjuvant (before surgery) chemotherapy - had surgery that removed all disease in the breast and lymph nodes - restricted from strenuous activity but can walk and do work of a light or sedentary nature, e.g., light house work, office work - additional criteria apply (study staff will review)

Exclusion Criteria:

- women who are pregnant or breastfeeding - history of prior invasive breast cancer within past 3 years - peripheral neuropathy that is more than intermittent & mild - see link to clinicaltrials.gov for additional exclusion criteria

Conditions & Interventions

Interventions:
Drug: Placebo Administration, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Biological: Trastuzumab Emtansine, Drug: Tucatinib
Conditions:
Cancer
Keywords:
Breast Cancer, HER2 Positive Breast Cancer

More Information

Description: We are studying how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Kiran Lassi
Phase: PHASE3
IRB Number: MMCORC030